| 08:30 |
Registration |
| 09:00 |
Welcome
• Xavier Rolet, CEO, London Stock Exchange Group
|
| 09:05 |
Policy Keynote
• Lord Prior of Brampton, Parliamentary Under Secretary of State, Department for Business, Energy and Industrial, HMG
|
| 09:25 |
Markets Keynote
• James Mitford, Managing Director, JPM
|
| 09:35 |
Industry Keynote
• Sir Robert Lechler, Vice Principal, Kings College London
|
| 09:55 |
Info Shot
• Martin Murphy, CEO, Syncona
|
| 10:10 |
Panel I – Cell/Gene Therapies/Personalised Medicine Moderator: Jo Pisani, Partner, Strategy& (PwC) Panel:
• Jonathan Appleby, CSO,Cell and Gene Therapy, GSK
• Geoffrey Hamilton-Fairley, CEO, Oncimmune
• Mike Stocum, CEO, Inivata
• Darrin Disley, CEO, Horizon Discovery
|
| 10:40 |
Info Shot
• Shaun Chilton, CEO, Clinigen
|
| 10:55 |
Coffee and Networking |
| 11:25 |
Info Shot
• Louise Makin, CEO, BTG
|
| 11:40 |
Panel II – Oncology Moderator: Jim Kinnier-Wilson, Partner, Penningtons Manches Panel:
• Lauren Domas, Head of Strategy and Operations, BTG Interventional Oncology
• Eliot Forster, CEO, Immunocore
• Steve Arkinstall, CSO, Kymab
Gregg Sando, CEO, Cell Medica
|
| 12:10 |
Info Shot • James Ward-Lilley, CEO, Vectura |
| 12:25 |
Panel III – Anti Bacterial/microbiome Moderator: Sarah Haywood, CEO, MedCity Panel:
• Richard Mason, Head of J&J Innovation, London, J&J
• Graham Lumsden, CEO, Motif Bio
• Neil Murray, CEO, Redx
• Glyn Edwards, CEO, Summit
|
| 12:55 |
Closing Keynote (technology) – Eli Lilly & Co – Why the UK?
• Trafford Clarke, Managing Director, Lilly Research Centre
|
| 13:15 |
Closing remarks
• Michael Meade, Managing Director, Corporate Broking and Advisory, Numis
|
| 13:20 |
Lunch |
